N-(4-hydroxy-3-phenylsulfanylnaphthalen-1-yl)thiophene-2-sulfonamide | 708218-62-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(4-hydroxy-3-phenylsulfanylnaphthalen-1-yl)thiophene-2-sulfonamide
• CAS: 708218-62-6
• 化学式: C₂₀H₁₅NO₃S₃
• 分子量: 413.542
• InChiKey: ANWROCYWIBTMKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氯-1,4-萘醌 在 sodium dithionite 、 titanium(IV) chloride tetrahydrofuran 、 水 、 三乙胺 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 N-(4-hydroxy-3-phenylsulfanylnaphthalen-1-yl)thiophene-2-sulfonamide
  参考文献：
  名称：

  Identification of a Novel Family of BRAF^V600E Inhibitors

  摘要：

  The BRAF oncoprotein is mutated in about half of malignant melanomas and other cancers, and a kinase activating single valine to glutamate substitution at residue 600 (BRAF(V600E)) accounts for over 90% of BRAF-mediated cancers. Several BRAF(V600E) inhibitors have been developed, although they harbor some liabilities, thus motivating the development of other BRAF(V600E) inhibitor options. We report here the use of an ELISA based high-throughput screen to identify a family of related quinolol/naphthol compounds that preferentially inhibit BRAF(V600E) over BRAF(WT) and other kinases. We also report the X-ray crystal structure of a BRAF/quinolol complex revealing the mode of inhibition, employ structure-based medicinal chemistry efforts to prepare naphthol analogues that inhibit BRAF(V600E) in vitro with IC50 values in the 80-200 nM range under saturating ATP concentrations, and demonstrate that these compounds inhibit MAPK signaling in melanoma cells. Prospects for improving the potency and selectivity of these inhibitors are discussed.

  DOI：

  10.1021/jm3004416

文献信息

• Antiviral Compounds and Methods of Use Thereof
  申请人：Guenther Richard H.

  公开号：US20130071353A1

  公开（公告）日：2013-03-21

  Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.

  本文披露了逆转录病毒传播的抑制剂、使用这些抑制剂进行逆转录病毒感染的治疗和预防方法，以及包括这些抑制剂的制药组合物。
• SMALL MOLECULE INHIBITORS OF MCL-1 AND THE USES OF THEREOF
  申请人：WAYNE STATE UNIVERSITY

  公开号：US20140235702A1

  公开（公告）日：2014-08-21

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having sulfonamido-1-hydroxynaphthalene structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases.

  这项发明涉及药物化学领域。具体而言，该发明涉及一类新型小分子，具有磺酰胺基-1-羟基萘结构，可作为Mcl-1蛋白酶抑制剂，并可用作治疗癌症和其他疾病的治疗剂。
• Antiviral compounds and methods of use thereof
  申请人：Trana Discovery, Inc.

  公开号：US10098887B2

  公开（公告）日：2018-10-16

  Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.

  本研究公开了逆转录病毒传播抑制剂、使用这些抑制剂治疗和预防逆转录病毒感染的方法以及包括这些抑制剂的药物组合物。
• Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
  申请人：Baylor College of Medicine

  公开号：US10676455B2

  公开（公告）日：2020-06-09

  Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.

  本发明的实施方案包括治疗、预防和/或降低有需要的个体发生选自肌肉萎缩、肌无力、恶病质及其组合的疾病的风险或严重程度的方法。在某些实施方案中，采用特定的小分子来治疗、预防和/或降低肌肉萎缩的风险。至少在特定情况下，小分子是 STAT3 的抑制剂。
• STAT3 INHIBITORS
  申请人：Tweardy David J.

  公开号：US20100041685A1

  公开（公告）日：2010-02-18

  Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.